Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Group 1 - Nektar Therapeutics (NASDAQ: NKTR) is preparing for a significant catalyst in June 2025, with the upcoming release of data from its phase 2b REZOLVE-AD study [2] - The REZOLVE-AD study is evaluating the use of REZPEG (NKTR-358) [2] Group 2 - The Biotech Analysis Central service offers in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [1][2]